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Objectives: Patients with a newly diagnosed non-small cell lung cancer (NSCLC) stage IIIB are 
offered chemoradiotherapy, as proposed by the current guidelines. This combination treatment 
is facilitated by the coexistence of corresponding departments in the same establishment. The 
geographical disparity of these health facilities influences patients’ willingness to be treated 
and may influence their survival. This is an observational study that compares the survival of 
two groups of patients with NSCLC stage IIIB: those treated with chemoradiotherapy versus 
those treated only with chemotherapy. These two comparable groups were formed exclusively 
by patients’ and/or their families’ decisions.
Methods: One hundred fifteen consecutive NSCLC stage IIIB patients were included in the 
study. All were hospitalized in the biggest Chest Disease Hospital in Athens and were offered 
sequential chemoradiotherapy. Only 54 patients opted for the proposed treatment, while 
61 decided to be treated with chemotherapy only, denying continuing their treatment in another 
health care unit (radiotherapy). Their survival and related factors were analyzed.
Results: Mean overall survival was estimated 10 months (95% confidence interval [CI]: 
7.96–12.04). Patients treated with chemoradiotherapy had almost double overall survival 
compared to those under chemotherapy (P = 0.001): 13.6 months (95% CI: 12.3–14.9) versus 
7.5 (95% CI: 6.1–8.9). Patients aged # 65 years (P , 0.001), smokers (P , 0.001), and those 
without a cancer history (P , 0.001) survived longer.
Conclusions: The lack of a radiotherapy department in a hospital providing chemotherapy 
impedes the application of current guidelines advocating combined radiochemotherapy. When 
recommended radiotherapy after six chemo cycles, half of the patients are unwilling to be 
displaced and do not follow the recommendations. This has an impact on patient survival.
Keywords: non-small cell lung cancer, survival, radiotherapy, chemotherapy, health 
facilities
Introduction
Lung cancer remains the leading cause of cancer deaths in both men and women, 
with approximately 1 to 2 million patients dying every year worldwide.1 Lung cancer 
causes more deaths than the next four most common cancers combined (colon, breast, 
pancreas, and prostate).2
Survival of patients with unresectable non-small cell lung cancer (NSCLC) stage 
IIIB remains dramatically poor. The treatment of advanced NSCLC includes two 
therapeutic options: chemo- and radiotherapy. Initial evidence suggested that combining 
radiotherapy with cisplatin alone or a cisplatin-based regimen modestly improves 
the median survival though the combined treatment compared with radiotherapy alone 
does not seem to improve the survival at 1 and 2 years.3 Later reports suggested that the Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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addition of chemotherapy to radiotherapy improves survival 
in patients with locally advanced NSCLC.4
The use of concurrent chemo-radiotherapy in patients 
with advanced NSCLC was shown to be associated with a 
14% reduction in death risk at 2 years compared to sequential 
chemoradiotherapy and with a 7% reduction of the same 
risk compared to radiotherapy alone. Nevertheless, toxicity 
concerns (mainly, acute oesophagitis and myelosuppression) 
did not permit the generalization of this type of therapeutic 
schedule.5 Theoretically, a sequential approach is mainly 
directed at eradication of micrometastatic disease, though 
concerns have been raised that the delay of radiotherapy 
resulting from the initial administration of chemotherapy 
allows for the accumulation of treatment-resistant clonogenic 
cells and decreases locoregional control.6 Combined modality 
therapy became the standard of care for NSCLC stage IIIB 
patients with good performance status.
In our hospital, which is the biggest chest disease hospital 
in Athens, patients with a newly diagnosed inoperable 
NSCLC stage IIIB and performance status 1 are offered 
the combined treatment proposed by the current guidelines. 
However, the concomitant version is not applicable due to the 
lack of a radiotherapy department. To receive the sequential 
version, patients have to displace to other hospitals across 
the Athens area. During the announcement of therapeutic 
schedule, patients and/or their families are informed that 
they could receive chemotherapy in the hosting hospital 
but that they have to displace to another hospital in order 
to receive radiotherapy. A number of patients are willing 
to opt for proposed displacement, while others opt for the 
least time-consuming treatment, namely chemotherapy, 
despite the existing scientific consensus that advocates the 
combined treatment. The patients decisions created two 
groups: patients treated with chemoradiotherapy versus 
those treated only with chemotherapy. The main end point of 
our study was to compare the survival of these two groups. 
Factors other than treatment modalities that were related to 
survival were also analyzed.
Methods
We conducted an observational study that recruited 
115 consecutive patients with NSCLC stage IIIB between 
January 2002 and December 2008. Demographic variables, 
such as age, gender, and smoking habits were registered. 
Familial and personal cancer histories were also recorded. 
Tumor-related data included tumor histotypes and stage 
(TNM; WHO version 6).7
All patients received chemotherapy (a doublet of a 
platinum agent and docetaxel). The patients receiving the 
combined therapy were also treated with radical sequential 
radiotherapy. All patients completed six cycles of first-line 
chemotherapy. Fourteen patients of each group received 
second-line chemotherapy (vinorelbine plus gemcitabine) 
(Table 1). Patients and their families were informed, treated, 
and followed-up by the same medical staff, either in the 
hosting hospital or in the radiotherapy clinic.
Table 1 Patients’ epidemiological and clinical characteristics
Main features Chemoradiotherapy 
(n = 54)
Chemotherapy 
(n = 61)
n Percentage % n Percentage %
smoking Yes 47 87 52 85.2
no 7 13 9 14.8
sex Male 49 90.7 53 86.8
Female 5 9.3 8 13.2
Age #65 33 61.1 31 50.8
.65 19 38.9 30 49.2
Histological subtypes nsCLC 54 46.9 61 53.1
sQCLC 22 40.7 22 36
ADC 17 31.5 23 37.7
LCLC 0 0 2 3.3
nsCLCx 15 27.8 14 23
Cancer history Yes 7 12.9 6 9.8
no 47 87.1 55 90.2
COPD Yes 19 35.2 23 37.7
no 35 64.8 38 62.3
second-line 
chemotherapy
Yes 14 26 14 23
no 40 74 51 77
Abbreviations: ADC, adenocarcinoma; COPD, chronic obstructive pulmonary disease; LCLC, large cell lung cancer; NSCLC, non-small cell lung cancer; NSCLCx, undefined 
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External beam radiotherapy was administered with 
18 MV linear accelerator (SL20; Elekta, Norcross, GA) 
photons. Treatment fields encompassed the primary tumor 
and the involved lymph nodes with an appropriated safety 
margin. Computerized planning was utilized to deliver the 
required dose to the target volume while keeping the spinal 
cord dose below 45 Gy and V20 below 35%. Continuous-
course treatment up to a total dose of 60 Gy in 30–33 daily 
fractions of 1.8–2 Gy (depending on the irradiated volume) 
was delivered over 6–7 weeks.
The course of the disease was followed. All patients 
and/or their families gave their written informed consent 
and the study was approved by the Ethics Committee of our 
hospital.
Statistical analysis
All analyses were performed using SPSS software (version 
15.0; SPSS Inc., Chicago, IL). The Kaplan–Meier method 
was used to estimate survival in all groups. The survival 
times were not censored. Differences in the length of time 
to death were tested with the log-rank test (Mantel–Cox) 
if proportional hazard was identified as true or Breslow 
test (generalized Wilcoxon) when proportional hazard was 
identified as false. A secondary analysis was performed by 
using multivariate Cox regression analysis to estimate the 
hazard function. Statistical limits for removing and entering 
variables from the stepwise model were P = 0.10 and 
P = 0.05, respectively. All hazard ratios were estimated by 
the maximum likelihood estimator according to the Breslow 
method. Reported values were two-sided. The significant 
level for all tests was determined at P = 0.05 (5%).
Results
Description of the cohort
This study included 115 consecutive patients suffering from 
NSCLC stage IIIB. Their sex ratio was 102/13 (M/F). Their 
mean age (±SD) was 64.45 (±6.7) years. The majority were 
smokers (n = 99), with mean tobacco consumption 76 per/year. 
Their most frequent comorbidity was chronic obstructive pul-
monary disease (COPD). Table 1 summarizes the main epide-
miological and clinical characteristics of the two groups.
survival
Acute radiation toxicity was minimal and there were no 
significant late toxicities. The mean overall survival of the 
cohort was estimated 10 months (95% CI: 7.96–12.04) 
(Figure 1). Survival was correlated to histological subtypes: 
patients with squamous NSCLC presented a mean survival 
of 10.7 months and those with ADC 10 months. These 
differences were significantly different in men (log-rank, 
Mantel–Cox: P = 0.002; Breslow [generalized Wilcoxon]: 
P = 0.002) but not in women. Furthermore, these differ-
ences manifested among smokers (log-rank, Mantel–Cox: 
P = 0.003; Breslow (generalized Wilcoxon): P = 0.002) but 
not among nonsmokers.
Survival was significantly different between the 
two studied groups (log-rank test; P = 0.001) in favor of the 
combined therapy arm (Figure 2). Patients receiving the com-
bined treatment presented an almost double mean survival 
compared to those who received only chemotherapy (13.6 
(12.3–14.9) versus 7.5 (6.1–8.9) months). This difference 
was manifest only among male patients (P , 0.001). Taking 
65 years as a cutoff, we observed that the above-mentioned 
difference concerned only patients aged under 65 years 
(P , 0.001), while it subsided for patients aged above 
65 years. The benefit of chemoradiotherapy is founded among 
smokers, while it was not demonstrated among nonsmokers. 
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Figure 1 Overall survival of patients with non-small lung cancer stage iiiB.
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Figure  2  Overall  survival  of  chemotherapy-treated  lung  cancer  patients  who 
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This difference appeared for patients without cancer history 
(P , 0.001), but not for those with such a history.
Discussion
This is an observational study that compares the survival of 
two groups of patients with NSCLC stage IIIB: those treated 
with chemoradiotherapy versus those treated only with 
chemotherapy. These two comparable groups were formed 
exclusively by patients’ and/or their families’ decision. The 
same medical team provided the information to patients and 
their environment. No sociocultural differences were noted 
between patients of the two groups. Thus, this study is able 
to provide data that resulted from a pragmatic situation in a 
chest medicine department.
During the last two decades, different studies have tried 
to explain the reasons why doctors and patients sometimes 
do not follow the guidelines.8–10 Guidelines are recommenda-
tions regarding clinical behavior, and their implementation 
is a complex process that is influenced by various factors, 
related both to the characteristics of guidelines themselves 
and to the social, organizational, economic, and political 
context or to implementation strategies. Following the guide-
lines most of all depends on the characteristics linked to the 
doctor and patient’s subjectivity, which can be a real obstacle. 
Knowledge, attitude, skills, experiences, beliefs, and values 
play a fundamental role for both physicians and patients.8 
In addition, treatment guidelines and strategies are based 
on data from randomized controlled trials and observational 
clinical studies. These sources drive treatment decisions, yet 
the data they provide may have limited relevance to the wider 
population in real-world clinical practice.10
The current first line therapeutic option for patients with 
NSCLC stage IIIB includes platinum-based chemotherapy 
in combination with a third-generation agent.11 Cytotoxic 
chemotherapy has resulted in improvements in both median 
overall survival and 1-year survival rates compared with 
the best supportive care.12 Concurrent or sequential radio-
therapy is proposed as a complement of chemotherapy. Both 
add years in terms of survival and palliation of symptoms 
according to the relative literature.11,13–15
The major finding of this study is the confirmation that 
patients with NSCLC stage IIIB gain in terms of survival 
from chemoradiotherapy. Patients who received this treatment 
presented an almost double mean survival compared to those 
who received only chemotherapy (13.6 versus 7.5 months). 
Among the group of patients who were treated with chemo-
radiotherapy, special subgroups gained more from combined 
therapy. Statistically significant differences were observed in 
younger patients (aged under 65 years), males, smokers, and 
patients without cancer history. Using the relative risk model, it 
was found that the mortality risk for the chemotherapy-treated 
lung cancer patients who did not receive radiotherapy was 
independent of the histological subtype of their tumor.
Although, more than 50% of NSCLC patients are diag-
nosed over the age of 65 years and approximately one-third 
of all patients are over the age of 70 years. Elderly patients 
are often undertreated. Furthermore, patients older than 
70 years are under-represented in clinical trials.16 Elderly 
patients are expected to tolerate chemotherapy poorly com-
pared to their younger counterpart, because of the progressive 
reduction of organ function and comorbidities related to age.17 
Retrospective analyses suggest that the efficacy of platinum-
based chemotherapy is similar in older and younger patients, 
with increased but acceptable toxicity for elderly patients. 
Therefore, the outcomes in the elderly mirror results observed 
in younger patients, although toxicity is generally greater.18
Males and smokers are overrepresented in our cohort; 
therefore no conclusion can be drawn regarding correspond-
ing findings. Patients with cancer history seem to be affected 
by more aggressive tumors, which result in less responsive-
ness to combination therapy.19 Nevertheless, in a recent 
study, patients with NSCLC and a previous malignancy did 
not show a significantly different survival rate than NSCLC 
patients without history of malignancy.20
The lack of a radiotherapy department in our hospital 
renders impossible the application of concurrent chemo-
radiotherapy, and therefore leads to the application of the 
sequential module. The benefits and risks of this option were 
clearly explained to the patients and/or their families and 
they were free to make their own decision. Many patients 
or their families believed that radiotherapy could cause 
more adverse events than any gain in the quality of life and 
survival. The majority were discouraged by the need to 
change hospital and medical staff. These subjective attitudes 
provoked inequalities in the offer of the proposed treatment. 
In our study, the need for displacement from one hospital to 
another was the major complaint of the patients.
Selection biases may as well interfere into the patients’ 
attitudes vis-à-vis the combined treatment (willingness to 
be treated, social support, socioeconomic status). The pres-
ence of a radiotherapy department in our hospital would 
have alleviated the inequality in the offered treatment. In any 
case, we had the opportunity to assess the role of the patients’ 
willingness in the application of proposed guidelines for a 
disease with poor prognosis, as is the case for inoperable 
lung cancer.Cancer Management and Research
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Conclusion
The lack of a radiotherapy department in a hospital providing 
chemotherapy impedes the application of current guidelines 
advocating the sequential chemoradiotherapy. When 
recommended radiotherapy after six chemo cycles, half of 
the patients are unwilling to be displaced and do not fol-
low the recommendations. This has an expected impact on 
patients’ survival.
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